Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Cash from Financing Activities: 2022-2023

Historic Cash from Financing Activities for Therapeutics (LENZ) over the last 2 years, with Dec 2023 value amounting to -$1.9 million.

  • Therapeutics' Cash from Financing Activities fell 883.20% to -$1.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $80.9 million, marking a year-over-year change of. This contributed to the annual value of $199.0 million for FY2024, which is 146.59% up from last year.
  • Latest data reveals that Therapeutics reported Cash from Financing Activities of -$1.9 million as of Q4 2023, which was down 236.44% from -$568,000 recorded in Q3 2023.
  • Therapeutics' Cash from Financing Activities' 5-year high stood at $83.2 million during Q1 2023, with a 5-year trough of -$1.9 million in Q4 2023.
  • Over the past 2 years, Therapeutics' median Cash from Financing Activities value was $92,500 (recorded in 2022), while the average stood at $13.5 million.
  • Data for Therapeutics' Cash from Financing Activities shows a maximum YoY tumbled of 883.20% (in 2023) over the last 5 years.
  • Therapeutics' Cash from Financing Activities (Quarterly) stood at $244,000 in 2022, then tumbled by 883.20% to -$1.9 million in 2023.
  • Its Cash from Financing Activities stands at -$1.9 million for Q4 2023, versus -$568,000 for Q3 2023 and $83.2 million for Q1 2023.